Trends in the Engineering of Adeno-Associated Virus (AAV) for Precision Gene Delivery to the Central Nervous System (CNS)
International Journal of Molecular Sciences · 23.06.2026 · 27 (13) · 5668
DOI: 10.3390/ijms27135668 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.06.2026. Verfasst von Sola Oloruntimehin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Virology, E.I. Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, Clinical Center, I.M. Sech…. Hauptthemen laut MEDLINE: Dependovirus, Genetic Therapy, Gene Transfer Techniques, Central Nervous System. Die Arbeit nennt 211 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov, First Moscow State Medical University of the Ministry of Health of the Russ….
Abstract (Originalsprache)
Rare genetic disorders of the central nervous system (CNS) remain some of the most complex and challenging diseases to treat for several reasons. Targeting the CNS, especially the brain, presents one of the greatest obstacles in gene therapy using adeno-associated virus (AAV) vectors. Although various AAVs have been identified for their ability to transduce different cells in the CNS, their effectiveness and efficiency are significantly limited by the presence of neutralising antibodies (NAbs) and restricted cargo capacity. Despite these challenges, our understanding of AAV structure and technological advances continue to enable researchers to develop innovative strategies that have resulted in groundbreaking, FDA-approved therapeutic products now available for Leber congenital amaurosis (LCA) (Luxturna®), spinal muscular atrophy (SMA) (Zolgensma®), and the two recent gene therapy products for aromatic L-amino acid decarboxylase (AADC) deficiency, Kebilidi® and Upstaza®, which currently hold FDA and EMA approval, respectively. This review aims to highlight recent advances in the field of AAV gene therapy for neurological disorders, identify research gaps, and suggest areas for future investigation to enable potential breakthroughs particularly in neurodegenerative, neurodevelopmental, and neuromuscular disorders. We foresee that more tissue- and cell-specific AAV vectors designed using AI-powered platforms will emerge to precisely and efficiently target specific brain regions, transforming how CNS disorders are treated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Molecular Virology, E.I. Martsinovsky Institute of Medical Parasitology, Tropical and Vector-Borne Diseases, Clinical Center, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia.
ORCID-Profile: Sola Oloruntimehin
Förderung
- Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov, First Moscow State Medical University of the Ministry of Health of the Russ…
Zitieren
APA
Oloruntimehin, S., & Malogolovkin, A. (2026). Trends in the Engineering of Adeno-Associated Virus (AAV) for Precision Gene Delivery to the Central Nervous System (CNS). International Journal of Molecular Sciences, 27(13), 5668. https://doi.org/10.3390/ijms27135668
Vancouver
Oloruntimehin S, Malogolovkin A. Trends in the Engineering of Adeno-Associated Virus (AAV) for Precision Gene Delivery to the Central Nervous System (CNS). International Journal of Molecular Sciences. 2026;27(13):5668. doi:10.3390/ijms27135668
BibTeX
@article{Oloruntimehin2026,
author = {Oloruntimehin, Sola and Malogolovkin, Alexander},
title = {Trends in the Engineering of Adeno-Associated Virus (AAV) for Precision Gene Delivery to the Central Nervous System (CNS)},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {13},
pages = {5668},
doi = {10.3390/ijms27135668}
}
EUVIMED